Skip to main content

Table 5 Association of PSA levels with SUVmax of the primary prostatic tumour and distribution of metastasis on [18F]PSMA-1007 PET/CT

From: Risk of metastatic disease using [18F]PSMA-1007 PET/CT for primary prostate cancer staging

 

PSA levels (ng/mL)

p-value

 ≤ 10

10–20

 > 20

n = 101

n = 50

n = 43

SUVmax of primary tumour (n = 187), median (IQR)a

13.9 (7.7–22.8)

17.4 (11.9–29.9)

21.5 (16.2–36.3)

 < 0.001

Regional nodes (n = 194), %(n/Total)b

14.9% (15/101)

18.0% (9/50)

41.9% (18/43)

0.001

Non-regional nodes (n = 194), %(n/Total)c

5.0% (5/101)

6.0% (3/50)

23.3% (10/43)

0.004

Bone metastasis (n = 194), %(n/Total) b

17.8% (18/101)

16.0% (8/50)

32.6% (14/43)

0.087

Visceral metastasis (n = 194), %(n/Total)c

3.0% (3/101)

2.0% (1/50)

7.0% (3/43)

0.51

  1. aKruskal–Wallis-test
  2. bChi-squared test
  3. cFisher’s exact test